CTX-471 + Tovecimig for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Feb 2026: Trial registered, NCT07392957
  2. 16 Jun 2026: Trial started, NCT07392957

The trials

NCT07392957: Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

State
Under way
Phase
Phase 1 and Phase 2
People
54 planned
Started
16 Jun 2026
Primary completion
30 Jun 2029
Arms
Phase IB Arm 2: CTX-009 and CTX-471 combination therapy, Phase II Expansion Arm 2: CTX-009 and CTX-471 combination therapy
Results
None posted
  1. 6 Feb 2026: Trial registered
  2. 16 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.